We are live on ! Find out more
UBIO

Proshares UltraPro NASDAQ Biotechnology

Delisted

UBIO was delisted on the 27th of March, 2020.

8 hedge funds and large institutions have $4.37M invested in Proshares UltraPro NASDAQ Biotechnology in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

79,950% more call options, than puts

Call options by funds: $1.6M | Put options by funds: $2K

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

300% more funds holding

Funds holding: 28 (+6)

112% more capital invested

Capital invested by funds: $2.06M → $4.37M (+$2.31M)

Holders
8
Holders Change
+6
Holders Change %
+300%
% of All Funds
0.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
1
Reduced
Closed
1
Calls
$1.6M
Puts
$2K
Net Calls
+$1.6M
Net Calls Change
+$1.51M
Name Holding Trade Value Shares
Change
Change in
Stake
VF
1
Virtu Financial
New York
$1.47M +$1.35M +25,445 New
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$1.3M +$1.19M +22,553 New
Jane Street
3
Jane Street
New York
$651K +$596K +11,252 New
VKH
4
Virtu KCG Holdings
New York
$322K +$295K +5,573 New
CT
5
CMT Trading
Illinois
$250K +$185K +3,496 New
CG
6
Cutler Group
California
$171K +$157K +2,970 New
TRCT
7
Tower Research Capital (TRC)
New York
$167K +$153K +2,897 New
UBS Group
8
UBS Group
Switzerland
$31K +$7.94K +150 +38%
BAMS
9
Bellevue Asset Management (Switzerland)
Switzerland
-$2.04M -7,000 Closed

UBIO Hedge Fund Activity: Q4 2015 in Review

8 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q4 2015, worth a combined $4.37M — up 112% from $2.06M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new UBIO positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $1.35M. The largest seller was Bellevue Asset Management (Switzerland), exiting entirely with an estimated $2.04M sold.

  • 8 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q4 2015, up from 2 in Q3 2015.
  • Funds reported $4.37M of Proshares UltraPro NASDAQ Biotechnology stock for Q4 2015, up 112% quarter-over-quarter.
  • 7 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q4 2015 and 1 closed out, a net change of +6 holders.
  • The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q4 2015 was Virtu Financial, an estimated $1.35M added.
  • The largest Proshares UltraPro NASDAQ Biotechnology seller in Q4 2015 was Bellevue Asset Management (Switzerland), an estimated $2.04M sold.

Based on aggregated 13F filings for Q4 2015.